B2BinPay v20 Increases Functionality with TRX Staking and Broader Blockchain Support
6.6.2024 11:31:00 EEST | Business Wire | Press release
The industry-leading blockchain platform, B2BinPay, has improved even further. The most recent version offers clients more flexibility and efficiency by expanding blockchain functionality and introducing TRX staking. Let's review how these new features improve B2BinPay's user experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606092849/en/
B2BinPay version 20 arrives with TRX staking feature and expanded blockchain support (Graphic: Business Wire)
TRX Staking – Earn While You Transact!
The launch of TRX Staking, based on the advanced Stake 2.0 mechanism developed by the TRON community, is a crucial highlight of B2BinPay v20. With its increased flexibility, simplified user interface, and improved resource delegation and utilisation efficiency, this new approach surpasses the previous Stake 1.0.
TRX staking empowers B2BinPay clients to stake any amount of TRX and earn a passive annual yield of 3-5% (subject to network conditions). But this is not all. By staking TRX, users can significantly reduce transaction fees on the TRON network. Staked TRX is converted into bandwidth and energy, two necessary resources, to achieve this.
Smart contracts run on energy, and transaction processing capability is provided by bandwidth. By staking TRX and acquiring these resources, companies and individuals can increase transaction efficiency and save operating costs, providing them a distinct competitive advantage.
Getting started with TRX Staking on B2BinPay is straightforward:
➔ Begin by converting your TRX into either Bandwidth or Energy based on the specific processing needs of your chosen asset type.
➔ After that, delegate your votes converted from Bandwidth or Energy to SR.
New Blockchains Supported
Building on the previous integration of Polygon and Avalanche, the addition of Optimism, Arbitrum, and Base—all of which provide native support for stablecoins—significantly broadens B2BinPay v20's support for blockchain technology.
Optimism
Optimism is a Layer 2 solution that scales the Ethereum leading network by batching transactions. It collects transaction data from the Ethereum blockchain, processes it in batches, and sends it back to the Ethereum mainnet for validation. Since its launch in 2021, Optimism has reduced fees by ten times compared to Ethereum's base level. Users have saved over $1 billion in gas payments, making it one of the most cost-effective blockchains.
Arbitrum
Arbitrum is an Ethereum scaling solution that increases transaction volumes while lowering costs. It shares Ethereum's tooling, enabling developers to deploy DApps on Arbitrum quickly and securely. This compatibility extends to stablecoins, offering users more choices.
Base
Base, developed by Coinbase, optimises Optimism’s OP Stack for enhanced EVM compatibility. This open-source rollup supports stablecoins and makes code deployment easier on Ethereum and compatible blockchains.
Why Does Expanded Blockchain Support Matter for Clients?
By incorporating additional blockchains, B2BinPay expands the range of transaction options, aligning with your business requirements using suitable technology. Specifically, B2BinPay now supports:
USDT on 7 networks:Ethereum, Binance Smart Chain, Tron, Avalanche, Polygon, Optimism, and Arbitrum.
USDC on 8 networks: Ethereum, Binance Smart Chain, Tron, Avalanche, Polygon, Optimism, Arbitrum, and Base.
Bridged USDC on 4 networks: Avalanche, Polygon, Optimism, and Arbitrum.
Here are other use cases of how the blockchain expansion can benefit you.
Streamlining Withdrawals for End-Users
Suppose your end-user needs to withdraw funds in a currency that's not immediately available. In that case, B2BinPay allows for swift asset conversion to meet currency requirements and handle associated transaction fees, ensuring the timely fulfilment of withdrawal requests.
Reducing Blockchain Transaction Fees
If you aim to lower the cost of USDT transactions, B2BinPay offers an effective solution by allowing you to aggregate USDT from various blockchains, such as Ethereum or Optimism, into a single swap wallet.
Ensuring Liquidity for Trading Platforms
Suppose you have significant cryptocurrency funds and urgent requirements like stopouts on trading platforms. In that case, you can rely on B2BinPay's extensive blockchain support to quickly convert assets into the required currency for deposit. This feature assists you in maintaining liquidity and enables quick responsiveness to market demands.
Final Remarks
According to the official statements, Algorand and Solana will be introduced in the upcoming release. With this expansion, there will be 10 blockchains that enable stablecoin transactions, including those already used: Ethereum, Tron, Binance Smart Chain, Avalanche, Polygon, Optimism, Arbitrum, and Base.
Connect with B2BinPay and unlock your business potential with advanced blockchain payment processing solutions!
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240606092849/en/
Contact information
sales@b2binpay.com
+357 250-308-82
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level
Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 20:07:00 EEST | Press release
Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Helio Strap Pro represents the next evolution of Amazfit's Hybrid Training System, extending performance tracking beyond heart rate to help athletes bett
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 18:30:00 EEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom